Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic mutations. Such agents can have remarkable activity against some cancers, although antitumor responses are often heterogeneous, and resistance remains a clinical problem. To gain insight into factors that influen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wendel, Hans-Guido, de Stanchina, Elisa, Cepero, Enriqué, Ray, Sagarika, Emig, Michael, Fridman, Jordan S., Veach, Darren R., Bornmann, William G., Clarkson, Bayard, McCombie, W. Richard, Kogan, Scott C., Hochhaus, Andreas, Lowe, Scott W.
Formato: Artigo
Lenguaje:Inglês
Publicado: National Academy of Sciences 2006
Materias:
Biological Sciences
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1455409/
https://ncbi.nlm.nih.gov/pubmed/16651519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0602402103
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares